Celltrion Healthcare said Friday it has won in an appellate trial, filed by Janssen claiming that the Korean company’s Remsima, or Inflectra in America, had infringed on the latter’s patent.
According to Celltrion, the U.S. Federal Court of Appeal ruled on Thursday that Janssen's claim for equivalent infringement of Remsima's medium technology is untenable, as the Korean company was not infringing on Janssen's medium technology patent.
|Celltrion Healthcare’s Remsima|
The company said that the case was unusual because all three judges reached a unanimous decision just one day after Celltrion began its defense. Considering that it usually takes one or two months for the U.S. appeals court to hear arguments and make a decision, this case is exceptional in that the judges responded favorably to its defense and made the decision quickly.
Janssen filed a trial with the U.S. District Court in Massachusetts in March 2015, claiming that Celltrion's biosimilar Remsima infringed on its patent on a medium containing nutrients for culturing antibodies. In July 2018, the district court judged that Celltrion did not infringe on Janssen's medium patent, and Janssen's claim was unfair. However, Janssen appealed to the appellate court in December of that year.
Celltrion expects Remsima’s market share will expand in the U.S., as the patent litigation has ended with the latest decision, adding that it also can increase the production of Remsima in the U.S. through contract manufacturing organization contracts.
<© Korea Biomedical Review, All rights reserved.>